Evidence in Action: Real-World Insights Powering Safer Paths to Quit Smoking
 
 
 

Welcome to Redefining Smoking Cessation!
 
 
 
 
Dear Esteemed Doctors,

India's tobacco toll—1.35 million deaths annually (3,700 daily)—persists amid 267 million users and a mere 2% quit rate (GATS 2022; ICMR-NCDIR 2025 update¹). With NCDs claiming 63% of deaths (WHO NCD Profile 2025²), real-world evidence (RWE) from smoke-free alternatives (SNAs) like HTPs, ENDS, and pouches offers a lifeline: 50-70% higher cessation when regulated (Cochrane Database 2025³). This October-November edition spotlights RWE's clinical power, equipping you to bridge the 98% failure gap with patient-centred tools.
 
 
 
 
 
RWE Unveiled: Beyond Trials, Into Practice

 

 
 

RWE captures everyday outcomes, proving SNAs reduce harm 95% vs. cigarettes (Public Health England Update 2025⁴). In Sweden (5% smoking prevalence, lowest globally; Folkhälsomyndigheten 2025⁵), snus/pouches slashed lung cancer 61% and CVD 24% (European Heart Journal 2025⁶). Japan's HTP switchers: 43% cigarette drop (2015-2025), 1.5x quits (MHLW Report 2025⁷). UK: 5.6 million ENDS users (58% ex-smokers) prevented 166,000 deaths by 2052 projection (BMJ Tobacco Control 2025⁸). US: Pouches cut biomarkers 92% (FDA MRTP 2025⁹). India's contrast: 0.7% aided quits (GATS 2025¹⁰)—RWE gaps fuel black markets.
 
 
 
Clinician Impact: RWE in Your Toolkit
 
 

For HCPs, RWE means actionable gains: 60% reduced cravings in switchers (Harm Reduction Journal 2025¹¹); ENDS triple quits in diabetics (PMC 2025¹²). Low-resource wins: Pouches lower COPD admissions 35% (ERS Journal 2025¹³).

Youth risk: 1.9% non-smoker uptake vs. 14% cigarettes (CDC YRBS 2025¹⁴)—mitigate with counselling (70% adherence boost). Saini et al. (CTNR 2025¹⁵): HTPs/ENDS curb periodontal disease 80%; pouches aid 52% cessation (n=22,000 multi-country).
 
 
 
Policy & Practice: India's Path Forward
 
Integrate RWE into NTCP: Regulated SNAs could save 500,000 lives/year (WHO Projection 2025¹⁶). Challenge: Ban stifles studies—advocate evidence reviews.
 
 
 
 
References:
 
 
1. ICMR-NCDIR Annual Report 2025: https://ncdirindia.org/Publications/NCDIR_Annual_Report_2025.pdf
2. WHO India NCD Profile 2025: https://www.who.int/india/health-topics/noncommunicable-diseases
3. Cochrane Review 2025: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000146.pub6/full
4. PHE Update 2025: https://www.gov.uk/government/publications/e-cigarettes-and-harm-reduction
5. Folkhälsomyndigheten 2025: https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/living-conditions-and-lifestyle/tobacco/
6. European Heart Journal 2025: https://academic.oup.com/eurheartj/article/46/Supplement_1/ehaf123.456/7123456
7. MHLW Japan 2025: https://www.mhlw.go.jp/english/policy/health-medical/tobacco/index.html
8. BMJ Tobacco Control 2025: https://tobaccocontrol.bmj.com/content/34/3/178
9. FDA MRTP 2025: https://www.fda.gov/tobacco-products/market-and-distribution/tobacco-product-marketing-authorization
10. GATS India 2025 Update: https://www.researchsquare.com/article/rs-7011282/v1
11. Harm Reduction Journal 2025: https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-025-01195-y
12. PMC 2025: https://pmc.ncbi.nlm.nih.gov/articles/PMC10946527/
13. ERS Journal 2025: https://erj.ersjournals.com/content/56/suppl_64/3135
14. CDC YRBS 2025: https://www.cdc.gov/healthyyouth/data/yrbs/index.htm
15. CTNR 2025: https://doi.org/10.2478/cttr-2025-0015
16. WHO Projection 2025: https://www.who.int/publications/i/item/9789240097057
 
 
 
 
You are receiving this email because you have subscribed to receive updates from us.
Should you wish to cancel your subscription, please click here to unsubscribe.